文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型严重急性呼吸综合征冠状病毒2型疫苗第一剂和第二剂的有效性:奥地利一项关于混合免疫与自然免疫的全国性队列研究。

Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.

作者信息

Chalupka Alena, Riedmann Uwe, Richter Lukas, Chakeri Ali, El-Khatib Ziad, Sprenger Martin, Theiler-Schwetz Verena, Trummer Christian, Willeit Peter, Schennach Harald, Benka Bernhard, Werber Dirk, Høeg Tracy Beth, Ioannidis John P A, Pilz Stefan

机构信息

Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.

出版信息

Open Forum Infect Dis. 2024 Sep 19;11(10):ofae547. doi: 10.1093/ofid/ofae547. eCollection 2024 Oct.


DOI:10.1093/ofid/ofae547
PMID:39371370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11450622/
Abstract

BACKGROUND: We aimed to evaluate the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in previously SARS-CoV-2-infected adults in the general population of Austria during the Delta wave and with extended follow-up. METHODS: In a nationwide retrospective cohort study, we calculated age-, sex-, and nursing home residency-adjusted Cox proportional hazard ratios (HRs) of coronavirus disease 2019 (COVID-19) deaths, SARS-CoV-2 infections, and non-COVID-19 deaths from 1 October to 31 December 2021, and secondarily with extended follow-up to 30 June 2022. Relative vaccine effectiveness (rVE) is rVE = (1 - HR) × 100. RESULTS: Among 494 646 previously infected adults, 169 543 had received 2 vaccine doses, 133 567 had received 1 dose, and 190 275 were unvaccinated at baseline. We recorded 17 COVID-19 deaths (6 vaccinated, 11 unvaccinated) and 8209 SARS-CoV-2 infections. Absolute risk of COVID-19 deaths was 0.003%. rVE estimates for COVID-19 deaths and reinfections exceeded 75% until the end of 2021 but decreased substantially with extended follow-up. The risk of non-COVID-19 death was lower in those vaccinated versus unvaccinated. CONCLUSIONS: First and second SARS-CoV-2 vaccine doses appear effective in the short-term, but with diminishing effectiveness over time. The extremely low COVID-19 mortality, regardless of vaccination, indicates strong protection of previous infection against COVID-19 death. Lower non-COVID-19 mortality in the vaccinated population might suggest a healthy vaccinee bias.

摘要

背景:我们旨在评估在奥地利普通人群中,于德尔塔变异株流行期间以及延长随访期内,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗接种对既往感染过SARS-CoV-2的成年人的有效性。 方法:在一项全国性回顾性队列研究中,我们计算了2021年10月1日至12月31日期间,经年龄、性别和养老院居住情况调整后的新型冠状病毒肺炎(COVID-19)死亡、SARS-CoV-2感染和非COVID-19死亡的Cox比例风险比(HRs),并进行了延长至2022年6月30日的随访。相对疫苗有效性(rVE)为rVE = (1 - HR) × 100。 结果:在494646名既往感染过的成年人中,169543人接种了2剂疫苗,133567人接种了1剂疫苗,190275人在基线时未接种疫苗。我们记录了17例COVID-19死亡病例(6例接种疫苗,11例未接种疫苗)和8209例SARS-CoV-2感染病例。COVID-19死亡的绝对风险为0.003%。截至2021年底,COVID-19死亡和再感染的rVE估计值超过75%,但随着随访期延长大幅下降。接种疫苗者的非COVID-19死亡风险低于未接种疫苗者。 结论:SARS-CoV-2疫苗的第一剂和第二剂在短期内似乎有效,但随着时间推移有效性逐渐降低。无论是否接种疫苗,COVID-19死亡率极低,表明既往感染对COVID-19死亡有强大的保护作用。接种疫苗人群中非COVID-19死亡率较低可能提示存在健康的疫苗接种者偏倚。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c716/11450622/cf213823163a/ofae547f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c716/11450622/cf213823163a/ofae547f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c716/11450622/cf213823163a/ofae547f1.jpg

相似文献

[1]
Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.

Open Forum Infect Dis. 2024-9-19

[2]
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.

Eur J Clin Invest. 2024-3

[3]
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.

PLoS Med. 2022-9

[4]
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.

Lancet Microbe. 2022-12

[5]
Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.

Clin Infect Dis. 2022-8-24

[6]
Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.

Clin Infect Dis. 2023-1-13

[7]
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.

Lancet Infect Dis. 2022-6

[8]
Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.

PLoS Med. 2021-12

[9]
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.

N Engl J Med. 2022-3-31

[10]
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.

J Glob Health. 2022-7-9

引用本文的文献

[1]
Estimates of SARS-CoV-2 Infections and Population Immunity After the COVID-19 Pandemic in Austria: Analysis of National Wastewater Data.

J Infect Dis. 2025-6-2

本文引用的文献

[1]
Durability of immune responses to SARS-CoV-2 infection and vaccination.

Semin Immunol. 2024-5

[2]
Healthy vaccinee effect: a bias not to be forgotten in observational studies on COVID-19 vaccine effectiveness.

Pol Arch Intern Med. 2024-2-28

[3]
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.

Eur J Clin Invest. 2024-3

[4]
Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia.

Sci Rep. 2023-11-21

[5]
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity.

Cell Mol Immunol. 2024-2

[6]
Postacute sequelae of COVID-19 at 2 years.

Nat Med. 2023-9

[7]
Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19.

N Engl J Med. 2023-7-20

[8]
The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies.

BMJ. 2023-6-7

[9]
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.

Lancet. 2023-3-11

[10]
Efficacy and safety of COVID-19 vaccines.

Cochrane Database Syst Rev. 2022-12-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索